Eli Lilly and Company

Karuna Therapeutics, Inc.

James Allen Monn

Matthew John Valli

Darryle D Schoepp

Steven Marc Massey

David R Helton

Concepcion Pedregal-Tercero

Eric D Moher

Joseph P Tizzano

Lourdes Prieto

Carlos Montero Salgado

Steven Scott Henry

Mary Jeanne Kallman

David Scott Coffey

Luisa Maria Martin-Cabrejas

Steven Wayne Pedersen

Carmen Dominguez Fernandez

Dennis Michael Zimmerman

William H Lunn

David Edward Tupper

Bruce Anthony Dressman

Thomas Charles Britton

Stephen Richard Baker

Barry P Clark

Kirk Willis Johnson

Anne H Dantzig

Maria Angeles Martinez-Grau

Ana Belen Bueno Melendo

Stephanie Ann Sweetana

Francisco Javier Agejas-Chicharro

Alfonso De Dios

Kevin Matthew Gardinier

Mohammad Sadegh Zia-Ebrahimi

Jose Antonio Martinez Perez

Christopher David Beadle

Jose Alfredo Martin

Ivan Collado Cano

Michael Parvin Johnson

Lorena Taboada Martinez

Sonia Maria Gutierrez Sanfeliciano

Ivan Collado Caño

Gunnar Erik Jagdmann, Jr

Jesus Ezquerra-Carrera

Carmen Dominguez-Fernandez

David G Evans

Darrell Stephen Coleman

Nadia M Ahmad

Jason Myers

Emanuela Gancia

Fabien Jean Ghislain Roussel

Elizabeth Anne Skidmore

Niall Wagstaff

Giorgio Attardo

Teresa Tse Ki Man

Lesley Walton

Bruce William Shaw

Thomas Hallett Large

Jaime Gonzalo Blanco-Urgoiti

Alicia Marcos Liorente

Marc Francis Herin

Clifford Adam Schlecht

Dennis A Bennett

Barry Peter Clark

Teresa Tse Man

Eric David Moher

The invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their use in treating muscarinic acetylcholine receptor mediated disorders.

Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions

Provided herein are compounds comprising compounds of formula I and/or salts thereof;wherein at least one of R, R, R, R, R, R, R, R, R, R, R, R, and Ris fluorine, and the remainder are independently chosen from hydrogen and fluorine; and R, R, R, R, R, R, R, R, R, and Rare independently chosen from hydrogen and deuterium; with the proviso that when R, R, and Rare fluorine, then at least one of R, R, R, R, R, R, R, R, R, and Ris fluorine or at least one of R, R, R, R, R, R, R, R, R, and Ris deuterium. Also provided are medicaments comprising these compounds and methods for treating central nervous system disorders with the compounds and medicaments described herein.

Xanomeline derivatives and methods for treating neurological disorders

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.

Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist

The present invention provides novel mGlu2/3 agonists of the formula wherein R, R, and Rare as defined herein, for use in the treatment of neurological or psychiatric disorders.

MGlu 2/3 agonists

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.

MGLU2 agonists

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Methods of treatment using a prodrug of an excitatory amino acid

The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor. As such the compounds may be useful for treatment or prevention of disorders remedied by antagonism of the mGlu5 receptor, wherein Ar is phenyl or napthyl each of which may be substituted by one or more C-Calkyl, C-Calkoxy, C-Cacyl, halo, amino, nitro, cyano, hydroxy, C-Cacylamino, C-Calkylsulfonylamino, mono-, di- or trifluorinated C-Calkyl, substituents which may be the same or different and may bear a CONH, CONHCH, CON(CH), COH, COCH, OCF, CHNHCOCH, CHNH, CHN(CH), CHCN, CHOH, CHNHSOCH, CHN(CH)(CH)CN, CHN(CH)CH(CH), CHNHCH(CH), CHNH(CH)CH, CHNHCOR, CHNHCHCH, CHNHCHNHCOC(CH), or N(S(O)CH)substituent; Ris hydrogen, halo, R, CN, C(NOH)R, C(NO&#x2014;R)R, (CH)COR, (CH)OR, COR, CF, SR, S(O)R, S(O)R, COCHCOR, NHSOR, NHCOR, C(NOR)NH, CHOCOR, (CH)NH, CON(CH)(CH)NHCOR, COR, CONH, CSNH, C(NH)NHOR, (CH)N(CH), or CONHNHCOR; Ris 1,2-ethenediyl or 1,2-ethynediyl; Ris hydrogen or C-Calkyl; Ris C-Calkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof, or an N-oxide thereof. 

Pyridyl derivatives and their use as mGlu5 antagonists

Prodrugs of excitatory amino acids

This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders 

Compounds of the formula (I) in which R, Rand Xhave the meanings given in the specification, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system 

Excitatory amino acid receptor modulators

The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.

Potentiators of glutamate receptors

Growing community of inventors

Indianapolis, IN, United States of America

James Allen Monn